37671 |
Oncology; Respiratory System |
The different central nervous system efficacy among gefitinib, erlotin... |
TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379 |
정현애 |
2020 |
37670 |
Oncology; Respiratory System |
Ten-year patient journey of stage III non-small cell lung cancer patie... |
LUNG CANCER 2020 10.1016/j.lungcan.2020.05.033 |
정현애 |
2020 |
37669 |
Oncology; Respiratory System |
Real world data of durvalumab consolidation after chemoradiotherapy in... |
LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035 |
정현애 |
2020 |
37668 |
Oncology; Respiratory System |
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NS... |
J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018 |
정현애 |
2020 |
37667 |
Oncology; Immunology |
Nivolumab for esophageal squamous cell carcinoma and the predictive ro... |
CANCER IMMUNOL IMMUN 2020 10.1007/s00262-020-02766-7 |
정현애 |
2020 |
37666 |
Oncology |
HLA-corrected tumor mutation burden and homologous recombination de fi... |
ANN ONCOL 2020 10.1016/j.annonc.2020.04.004 |
정현애 |
2020 |
37665 |
Pharmacology & Pharmacy |
Evaluating entrectinib as a treatment option for non-small cell lung c... |
EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932 |
정현애 |
2020 |
37664 |
Oncology |
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell L... |
CANCER RES TREAT 2020 10.4143/crt.2020.278 |
정현애 |
2020 |
37663 |
Oncology |
Clinical outcomes of immune checkpoint inhibitors for patients with re... |
BMC CANCER 2020 10.1186/s12885-020-07214-4 |
정현애 |
2020 |
37662 |
Oncology; Immunology |
Clinical advantage of targeted sequencing for unbiased tumor mutationa... |
J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199 |
정현애 |
2020 |